Investor Relations

Press Releases


All Releases
View Summary SIGA Receives $8 Million in Financing Support from MacAndrews & Forbes
Jun 23, 2008
PDF 11.3 KB Add to Briefcase
View Summary SIGA Advances Dengue Antiviral Program
May 21, 2008
PDF 12.8 KB Add to Briefcase
View Summary SIGA Technologies Reports Operating Results for the First Quarter of 2008
May 12, 2008
PDF 12.0 KB Add to Briefcase
View Summary SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team
May 7, 2008
PDF 10.9 KB Add to Briefcase
View Summary SIGA Technologies to Announce First Quarter 2008 Results of Operations on May 12, 2008
May 6, 2008
PDF 11.4 KB Add to Briefcase
View Summary SIGA Begins Negotiations with Government Agency for Additional Funding to Accelerate ST-246 Commercial Scale Manufacturing
Apr 29, 2008
PDF 10.9 KB Add to Briefcase
View Summary Dr. Dennis E. Hruby, Chief Science Officer of SIGA Technologies, to Present CDC Distinguished Lecture on Smallpox Antiviral Drug ST-246
Apr 18, 2008
PDF 11.8 KB Add to Briefcase
View Summary SIGA Advances ST-246 Smallpox Antiviral Development in Europe
Apr 15, 2008
PDF 12.5 KB Add to Briefcase
View Summary SIGA Initiates Manufacture of ST-246 NDA Registration Batches
Apr 4, 2008
PDF 10.2 KB Add to Briefcase
View Summary SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial
Mar 27, 2008
PDF 12.3 KB Add to Briefcase
View Summary SIGA Files Application Supporting Emergency Use Approval for ST-246
Mar 24, 2008
PDF 12.2 KB Add to Briefcase
View Summary SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel
Mar 17, 2008
PDF 9.1 KB Add to Briefcase
View Summary SIGA to Present at Susquehanna's SIGnificant Options in Healthcare Conference
Feb 29, 2008
PDF 8.2 KB Add to Briefcase
View Summary SIGA to Present at The 26th Annual JPMorgan Healthcare Conference
Jan 7, 2008
PDF 7.2 KB Add to Briefcase
View Summary SIGA CEO, Dr. Eric Rose, Selected To Serve As Member of National Biodefense Science Board
Dec 20, 2007
PDF 7.4 KB Add to Briefcase
View Summary SIGA Completes 21 Day Multi-dose Human Clinical Safety And Dose-ranging Trial Of Its Lead Smallpox Drug ST-246
Dec 6, 2007
PDF 11.1 KB Add to Briefcase
View Summary SIGA Cheif Scientific Officer, Dennis Hruby To Present ST-246 Progress And Human Clinical Safety Study Data To The World Health Organization (WHO)
Nov 26, 2007
PDF 10.6 KB Add to Briefcase
View Summary SIGA Technologies to Announce Third Quarter 2007 Results Of Operations
Nov 8, 2007
PDF 7.9 KB Add to Briefcase
View Summary ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates
Sep 26, 2007
PDF 12.4 KB Add to Briefcase
View Summary SIGA Technologies To Join The Russell Microcap Index
Jun 19, 2007
PDF 9.1 KB Add to Briefcase
Showing 1-20 of 36 Page: 1 2  Next 20
= add release to Briefcase

© 2007 SIGA       Home       Contact